ACE2 and cancer: Potential immunosuppression, upregulated cytokine levels, changed expression of ACE-2 and TMPRSS2, and a prothrombotic state may exacerbate the effects of SARS-CoV-2 on cancer patients, have the potential to be exploited as biomarkers for serious diseases and therapeutic targets; and preliminary reports suggest that susceptibility to SARS-CoV-2 virus infection may be higher in cancer patients, but current evidence remains poor (34).